A bimodal closed-loop neuromodulation implant integrated with ultraflexible probes to treat epilepsy.

Anti-seizure medications and deep brain stimulation are widely used therapies to treat seizures; however, both face limitations such as resistance and the unpredictable nature of seizures. Recent advancements, including responsive neural stimulation and on-demand drug release, have been developed to address these challenges. However, a gap remains, as electrical stimulation provides only transient effects while medication has a delayed onset. To bridge this gap, we developed a Bimodal Closed-loop Neurostimulation Implant System that integrates real-time neural recording, immediate electrical stimulation, and on-demand drug release to achieve more effective seizure suppression. This dual-modality system combines rapid electrical intervention with sustained pharmacological treatment to provide comprehensive seizure control. An embedded platform powered by a Long Short-Term Memory network detects seizures and autonomously triggers these interventions. In vivo studies in an epileptic mouse model revealed that electrical stimulation achieved rapid seizure suppression, terminating 75.16% of seizures, with 90% of episodes suppressed within 10 s. The subcutaneous drug capsule provided additional control, with an onset of action approximately 15 min after release. The dual-modality approach bridged the gap between immediate and delayed intervention, stabilizing neural activity and reducing seizure recurrence. Furthermore, we confirmed the long-term viability of neurons, observing no significant changes in morphology or signal quality following stimulation and drug release. These results suggest that the system offers rapid, stable, and minimally invasive seizure control, making it a promising therapeutic tool for epilepsy. By bridging the gap between electrical effects and delayed pharmacological action, the system presents a novel approach to epilepsy management.